Effect of current treatment on long-term population survival data of pancreatic cancer patients

Česká verzia

Authors: Ryska M.
Authors place of work: Chirurgická klinika 2. LF UK a ÚVN – VFN Praha
Published in the journal: Gastroent Hepatol 2019; 73(5): 409-412
Category: Gastrointestinal Oncology: Review Article
doi: https://doi.org/10.14735/amgh2019409

Summary

Pancreatic cancer (PC) is the second most common cancer of the gastrointestinal tract and the sixth most common cancer in the Czech Republic. Late diagnosis means that more than 70% of patients are diagnosed in stage IV. The only chance for long-term survival of patients is multimodal treatment, in which radical resection plays a crucial role. It is clear from the population data of the CR in the period 1995–2016 that the number of patients treated in stages I and II of the disease has significantly increased: by three-fold in stage I and by two-fold in stage II. On the other hand, overall relative survival has increased from 3.5 to 5.4 % in the last 20 years, meaning that overall relative survival has increased by less than 2%.

Keywords:

Pancreatic cancer – multimodal therapy – population data

Zdroje

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362 (17): 1605−1617. doi: 10.1056/NEJMra0901557.

2. Nimura Y, Nagino M, Takao S et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012; 19 (3): 230−241. doi: 10.1007/s00534-011-0466-6.

3. Büchler MW, Wagner M, Schmied BM et al. Changes in morbidity after pancreatic resection. toward the end of completion pancreatectomy. Arch Surg 2003; 138 (12): 1310−1314. doi: 10.1001/archsurg.138.12.1310.

4. Ryska M, Rudiš J. Total pancreatectomy for pancreatic malignancy – from history to the present day. Rozhl Chir 2016; 95 (10): 345−349.

5. Kagedan DJ, Raju RS, Dixon ME et al. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. HPB 2016; 18 (4): 339–347. doi: 10.1016/j.hpb.2015.12.005.

6. Dušek L, Mužík L, Kubásek J et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http: //www. svod.cz.

7. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467 (7319): 1114−1117. doi: 10.1038/nature09515.

8. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19 (5): F9−F26. doi: 10.1530/ERC-12-0105.

9. Seufferlein T, Bachet JB, Van Cutsem E et al. Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii33–vii40. doi: 10.1093/annonc/mds224.

10. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987; 60 (9): 2284–2303. doi: 10.1002/1097-0142 (19871101) 60: 9<2284:: aid-cncr2820600930>3.0.co; 2-v.

11. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935; 102 (4): 763–776. doi: 10.1097/00000658-193510000-00023.

12. Gudjonsson B. Pancreatic cancer: 80 years of surgery – percentage and repetitions. HPB Surgery 2016. 6839687. doi: 10.1155/2016/6839 687.

13. Ducreux M, Cuhna AS, Caramella V et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5): v56−v68. doi: 10.1093/annonc/mdv295.

14. Cooper M, Newman NA, Ibrahim AM et al. Unnecessary tests and procedures in patiens presenting with solid tumors of the pancreas. J Gastrointest Surg 2013; 17 (7): 1218−1223. doi: 10.1007/s11605-013-2213-6.

15. Ryska M, Dušek L, Pohnán R et al. Kvalita života je důležitým faktorem indikační rozvahy u nemocných s karcinomem pankreatu. Multicentrická prospektivní studie. Rozhl Chir 2012; 91 (4): 199−208.

16. Tittelbach-Helmrich D, Abegg L, Wellner U et al. Insurance costs in pancreatic surgery: does the pecuniary aspect indicate formation of centers? Chirurg 2011; 82 (2): 154–159. doi: 10.1007/s00104-010-1953-z.

17. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol 2015; 42 (1): 8−18. doi: 10.1053/j.seminoncol.2014.12.002.

18. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69−90. doi: 10.3322/caac.20107.

19. Loveček M, Skalický P, Ryska M et al. Aktuální stav chirurgické léčby karcinomu pankreatu v České Republice. Rozhl Chir 2016; 95 (4): 151−155.